摘要
目的:评价吸入信必可都保治疗支气管哮喘的临床疗效及安全性。方法:对我院40例临床诊断哮喘的住院患者吸入信必可都保治疗,观察患者用药前及治疗后4、12周的临床症状变化、第1 s用力呼气容积(FEV1)、最大呼气峰流速值(PEF)、FEV1占预计值的百分比的变化。结果:通过治疗可显著改善患者临床症状、肺通气功能,治疗前后差异有统计学意义(P<0.05)。结论:吸入信必可都保可有效控制哮喘发作、改善肺功能,具有良好的依存性和安全性,值得临床推广应用。
Objective：To investigate the efficacy and safety of symbicort turbuhaler in the treatment of patients with bronchial asthma.Methods：40 cases treated by inhalation of symbicort turbuhaler,observe the change of clinical symptoms and pulmonary function（FEVl、FEV1%、PEF、PEF%）before treatment and 4 weeks、12 weeks after treatment.Results： The treatment by inhalation of symbicort turbuhaler can improve clinical symptoms and pulmonary ventilation function,showing significant difference after treatment compared with before treatment（P〈0.05）.Conclusions：Inhalation symbicort turbuhaler can better contro1 asthma symptoms and improve lung function.Patients show better compliances and safety.It is worthy of being applied more in clinical practice.
出处
《内蒙古医学杂志》
2009年第11期1318-1319,共2页
Inner Mongolia Medical Journal
